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Protein kinases are well known to transmit and regu-
late signaling pathways. To identify additional regula-
tors of the pheromone signaling apparatus in yeast, we
evaluated an array of 120 likely protein kinases encoded
by the yeast genome. Each kinase was fused to glutathi-
one S-transferase, overexpressed, and tested for
changes in pheromone responsiveness in vivo. As ex-
pected, several known components of the pathway
(YCK1, STE7, STE11, FUS3, and KSS1) impaired the
growth arrest response. Seven other kinases also inter-
fered with pheromone-induced growth arrest; in rank
order they are as follows: YKL116c (renamed PRR1) 5
YDL214c (renamed PRR2) > YJL141c (YAK1, SRA1) >
YNR047w 5 YCR091w (KIN82) 5 YIL095w (PRK1) >
YCL024w (KCC4). Inhibition of pheromone signaling by
PRR1, but not PRR2, required the glutathione S-trans-
ferase moiety. Both kinases inhibited gene transcription
after stimulation with pheromone, a constitutively ac-
tive kinase mutant STE11-4, or overexpression of the
transcription factor STE12. Neither protein altered the
ability of the mitogen-activated protein kinase (MAPK)
Fus3 to feedback phosphorylate a known substrate, the
MAPK kinase Ste7. These results reveal two new compo-
nents of the pheromone-signaling cascade in yeast, each
acting at a point downstream of the MAPK.
tein, as well as to effector targets within the nucleus (2). Sst2
promotes signal inactivation by accelerating Gpa1 GTPase ac-
tivity and promoting subunit reassembly (3). The casein kinase
I isoforms (Yck1, Yck2) promote signal inactivation by phos-
phorylating receptors, triggering their uptake and degradation
(4–6). Notably, most (if not all) of the signaling components
must exist as dimers to function. Prominent examples include
the receptor (7, 8) Ste5 and its associated kinases (9–11), as
well as the nuclear transcription factor Ste12 (12–15).
A central player in the kinase cascade is Fus3, a member of
the MAPK1 family. In mammals, MAPKs can respond to a
variety of signaling molecules and chemical or physical stresses
(temperature, salt, etc.) (16). MAPKs in turn regulate almost
all aspects of cell growth and homeostasis. In yeast, the MAPK
Fus3 phosphorylates and regulates proteins required for pher-
omone detection (Ste3), kinase scaffolding and activation (Ste5)
(17), morphological and cytoskeletal changes (Far1) (18–20),
cell division arrest (Far1) (19–21), transcriptional activation
(Ste12) (18, 22, 23), transcription inhibition (Dig1, Dig2) (24–
26), and feedback inhibition (Sst2) (27). In most cases, phos-
phorylation by Fus3 leads to enhanced signal transduction, but
in a few instances phosphorylation promotes signal attenua-
tion or desensitization. For instance, phosphorylation of the
receptor Ste3 leads to its endocytosis and degradation (28).
Phosphorylation of Sst2 leads to its stabilization and to further
inactivation of the G protein (27). Thus Fus3 allows a coordi-
nated response to pheromone in preparation for cell fusion,
with both positive and negative outcomes for signaling.
The completion of the yeast genome sequence has yielded a
complete inventory of 6144 open reading frames. Of these, 123
are likely to encode protein kinases, many of which have not
been characterized. Given the prominent role that kinases have
in G protein signaling and desensitization, we undertook a
comprehensive screen of these proteins for those affecting the
pheromone response in yeast. Here we describe two novel reg-
ulators of the G protein/MAPK cascade, which we have desig-
nated Prr1 and Prr2.
EXPERIMENTAL PROCEDURES
Strains, Plasmids, and Mutagenesis—Standard methods for the
growth, maintenance, and transformation of yeast and bacteria, and for
the manipulation of DNA, were used throughout (29). The yeast S.
cerevisiae strains used in this study were EJ 758 (MATa his3-200,
leu2-3, 112, ura3-52, pep4::URA3) (30), C699–32 (MATa bar1D::HisG
FUS1-lacZ ::LEU2 ade2 ste7::ADE2 his3 leu2 trp1 ura3 ssd1 can1),
BY4741 (MATa leu2D met15D ura3D), and BY4741-derived mutants
lacking FUS3 (YBL016w), PRR1 (YKL116c), and PRR2 (YDL214c; all
from Research Genetics, Huntsville, AL).
The following steps were used for construction by gene replacement
of strain C699–32 from strain C699 (identical to strain W303–1A)
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Many cell-signaling processes require the action of receptors, 
G proteins, and protein kinases that propagate the signal. In 
humans, G protein-coupled receptors respond to hormones, 
neurotransmitters, odors, taste, and light. In the yeast Saccha-
romyces cerevisiae, G protein-linked pheromone receptors trig-
ger events required for mating and cell fusion. Upon activation 
of the receptor (Ste2 or Ste3 in yeast), GTP binds to the G 
protein a subunit (Gpa1), which triggers its dissociation from 
the G protein bg subunits (Ste4/Ste18). Gbg in turn activates a 
protein kinase cascade comprised of Ste20, Ste11, Ste7, and 
Fus3 (1). Ste5 promotes signaling, through the assembly and 
recruitment of Ste11, Ste7, and Fus3, to the activating G pro-
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(from K. Nasmyth). The BAR1 locus was replaced with the
bar1D::HisG::URA3::HisG allele from the plasmid C1329 (from
K. Nasmyth). Loss of the URA3 marker was carried out by selection on
5-fluororotic acid-containing medium (31, 32). EcoRI-linearized
pNC2762 was used for integration of the FUS1-lacZ reporter gene at the
leu2 locus. Finally, the STE7 locus was replaced with the ste7D::ADE2
allele from pSL2270 (33).
For expression of kinase-GST fusions, plasmid pYEX 4T-2 (CLON-
TECH, Palo Alto, CA) (2 m, CUP1 promoter, URA3 and leu2-d, ampR,
GST) was modified by the addition of a 140-nucleotide recombination
domain, 39 of its EcoRI site, linearized within the recombination domain
by restriction digestion, and cotransformed with polymerase chain re-
action-amplified open reading frames that had the same ends as the
linearized plasmid, as described previously (34). For overexpression
without GST, each open reading frame was polymerase chain reaction-
amplified using Genepair primers (Research Genetics, Huntsville, AL),
which include start and stop codons and a universal flanking sequence,
and subcloned into the yeast expression vector pYES2.1/V5-His-TOPO
(2 m, URA3, GAL1 promoter, CYC1 terminator) (Invitrogen, Carlsbad,
CA). STE7 was expressed as a Myc epitope-tagged protein (Ste7M)
using pNC318 (CEN3-ARS1, CYC1 promoter, TRP1, ampR), as de-
scribed previously (35). STE11-4 was overexpressed using YCp50-
STE11-4 (2 m, URA3, ampR) (from George Sprague, University of Ore-
gon). STE12 was overexpressed using PFILZ-112.1 (TRP1, 2 m, ampR,
GAL1 promoter) (from Joseph Dolan, Medical University of South
Carolina).
The Lys to Arg mutations were constructed using the QuikChange
mutagenesis kit (Stratagene, La Jolla, CA). The mutagenic oligonucleo-
tides (plus complementary strands; not shown) are 59-CAT CGT GAT
TTA AAG CCC TCC AAC-39 (FUS3), 59-GGT CAC CGG CAA TTT GCT
GCT GAG TTT ATA GGG-39 (PRR1), and 59-CAA AAA CGT AAT TTC
CTT ATG TCC AGT TTC-39 (PRR2).
Pheromone-response Bioassays—For the pheromone-dependent
growth inhibition assay (halo assay), overnight cultures were grown in
selective media, and 100 ml was diluted with 2 ml of sterile water,
followed by the addition of an equal volume of 1% (w/v) dissolved agar
(55 °C), and poured onto an agar plate containing the same medium.
Sterile filter discs were spotted with synthetic a-factor pheromone and
placed onto the nascent lawn to induce growth arrest. The resulting
zone of growth-arrested cells was documented after 2 days.
For pheromone-dependent reporter transcription assays (36), strains
were grown for 36 h in dextrose selective medium and then diluted in
galactose selective medium to induce expression of the kinases. Mid-log
phase cells were then aliquoted (90 ml) to a 96-well plate and mixed with
10 ml of a-factor for 90 min, in triplicate. b-Galactosidase activity was
measured by adding 20 ml of a freshly prepared solution of 83 mM
fluorescein di-b-D-galactopyranoside (10 mM stock in Me2SO; Molecular
Probes), 137.5 mM PIPES, pH 7.2, 2.5% Triton X-100, and incubating for
90 min at 37 °C. The reaction was stopped by the addition of 20 ml of 1
M Na2CO3, and the resulting fluorescence activity was measured at
485-nm excitation, 530-nm emission.
Ste7 phosphorylation was monitored by immunoblotting. Cells were
grown in galactose selective medium to induce PRR1, PRR1-KR, PRR2,
PRR2-KR, FUS3, and FUS3-KR to a density of 1 3 107 cells per ml.
Protein extracts (150 mg) were prepared as described previously (37,
38), fractionated by SDS-polyacrylamide (10%) gel electrophoresis, and
transferred to nitrocellulose using a mini trans-blot electrophoretic
transfer cell (Bio-Rad) for 1 h at 110 V. 9E10 monoclonal antibodies (1.4
mg/ml) (39) were used to detect the Myc epitope-tagged form of Ste7
(Ste7M). The Promega Protoblot immunoblot system with anti-mouse
IgG alkaline phosphatase conjugate (0.13 mg/ml) was used to detect the
primary antibody by calorimetric methods. Protein concentrations were
determined using the Bio-Rad protein assay kit.
Bioinformatics—Prr2 homologues were identified with the advanced
BLAST algorithm using the Prr2 protein kinase domain as the query
(40). Multiple alignments of the Prr2 homologues were performed using
CLUSTAL W (41) with Phylip set as output. For the visualization of the
degree of relatedness among the Prr2 homologues in S. cerevisiae, the
CLUSTAL W alignment was imported into TREEVIEW (42). Nuclear
localization signals (NLS) were identified using the Internet version of
PSORT II (43). For the detection of classical NLS patterns, PSORT uses
the following two rules: four-residue pattern (pat4) composed of four
basic amino acids (Lys or Arg) or composed of three basic amino acids
(Lys or Arg) and either His or Pro; the other (pat7) is a pattern starting
with Pro and followed within three residues by a basic segment con-
taining Lys/Arg at three of four positions. Another type of NLS pattern
(bipartite) is two basic residues, a ten-residue spacer, and another basic
region consisting of at least three positions of five basic residues.
RESULTS
To identify novel proteins that regulate the mating pathway,
we screened an expression array of 120 (of 123 total) protein
kinases encoded by the yeast genome. Each open reading frame
was fused to GST and overexpressed in a high copy plasmid,
using the copper-inducible promoter from CUP1. Most of the
6144 open reading frames are available in this format and are
typically tested in arrayed pools containing a defined set of
gene products (30). Because we were primarily interested in
finding novel kinase regulators of the pathway, we elected to
test this subset of genes individually. Our approach has signif-
icant advantages over conventional genetic screening strate-
gies. First, it is quite rapid; each round of screening can be
conducted in about 2 weeks. Second, it is highly systematic,
allowing us to test nearly all of the likely kinases encoded by
the yeast genome, and provides immediate identification of the
gene responsible for a particular activity. Third, it is sensitive,
because each kinase is strongly overexpressed. Fourth, each
open reading frame is fused to GST, which will facilitate even-
tual purification and biochemical analysis of the encoded
kinase.
The following strategy was used to identify kinases that
promote or inhibit pheromone signaling. Transformed cells
were grown to saturation and plated on solid medium contain-
ing copper sulfate to induce kinase expression. a-Factor pher-
omone was spotted onto the nascent lawn, and the resulting
zone of growth inhibition was documented after 2–3 days (halo
assay). After screening all 120 clones in duplicate, the vast
majority yielded no difference in growth. None caused an in-
crease in halo size, whereas a few produced halos that were
smaller and/or more turbid than normal. Of these, 12 were
selected for further analysis and validation.
The following five of the 12 clones encode known kinases of
the pathway: YCK1, STE7, STE11, FUS3, and KSS1 (a MAPK
that can partially complement FUS3). The only other known
kinase in the pathway, STE20, was not included in the screen,
because it is one of three genes that could not be cloned into the
expression vector. Our ability to identify essentially all of the
known kinase components in the pathway indicates that our
screening strategy produced few false negatives. Further, re-
covery of all the expected kinases reinforces the idea that this
set is functionally relevant and that the seven other clones
identified in the screen are likely to have some role in phero-
mone signaling. These are as follows, in rank order of inhibi-
tory potency: YKL116c 5 YDL214c . YJL141c (YAK1,
SRA1) . YNR047w 5 YCR091w (KIN82) 5 YIL095w (PRK1) .
YCL024w (KCC4). Notably, the screen does not reveal whether
the other clones recovered here might have a positive or nega-
tive role in pheromone signaling. For instance, Ste11 and Ste7
are primarily needed to transmit the pheromone signal, yet
each inhibits the response in this overexpression method (see
below).
Pheromone-induced growth inhibition experiments with rep-
resentative kinases from the above set are shown in Fig. 1. In
this and all subsequent figures, FUS3 is used as a positive
control, whereas an irrelevant kinase or empty vector is used as
a negative control. The two most potent inhibitors were re-
named PRR1 (YKL116c) and PRR2 (YDL214c), for pheromone
response regulators 1 and 2. Because they had not previously
been implicated in the pheromone-response pathway, we fo-
cused our attention on their further characterization.
The halo assay is a convenient but fairly qualitative measure
of pheromone sensitivity. A more quantitative measure of pher-2 B. Errede, unpublished data.
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omone response can be obtained from analysis of transcrip-
tional induction, using a reporter comprised of the FUS1 pro-
moter and lacZ (b-galactosidase) gene. As shown in Fig. 2,
overexpression of either PRR1 or PRR2 results in a marked
inhibition of pheromone-dependent transcription. Compared
with the vector control, overexpression of Prr1 or Prr2 reduced
the maximum response at 30 mM a-factor by 1.24- and 2.77-fold,
respectively, with no change in EC50. Overexpression of our
positive control kinase Fus3 yielded an even larger (11.7-fold)
decrease in activity, as shown previously (44).
As noted above, the overexpression assays employed here do
not distinguish whether a given kinase has a positive or neg-
ative role in pheromone-induced signaling. It was shown pre-
viously through systematic gene disruption analysis that nei-
ther PRR1 nor PRR2 is essential for cell viability (45).
Therefore, the transcription response of deletion mutant
strains could be evaluated over a range of a-factor concentra-
tions. As shown in Fig. 3, the pheromone response in either the
prr1D or prr2D single mutant is identical to that of the wild-
type strain. By contrast, the pheromone response is diminished
with the control fus3D mutant. Although there is substantial
precedent and several reasons for single deletion mutants fail-
ing to give a phenotype, this outcome meant that different
strategies would be needed to establish whether PRR1 and
PRR2 act as positive or negative regulators (see below).
To determine where in the pathway Prr1 and Prr2 operate,
we examined their ability to inhibit signaling at different
points downstream of the pheromone receptor. For this analy-
sis, the pathway was activated in two alternative ways. In the
first case, we used an allele of the MAPK kinase kinase STE11
(STE11-4), containing a single amino acid substitution (T596I)
within the catalytic domain. Cells expressing STE11-4 exhibit
a significant increase in basal signal pathway activity (46).
Constitutive activation by STE11-4 is unaffected by mutations
in the receptor (Ste2) or Gb (Ste4) but is blocked by mutations
in the downstream MAPK kinase (Ste7), MAPK (Fus3, Kss1),
or transcription factor (Ste12) (46). Thus STE11-4 activates
signaling at a well defined step in the pathway, between Ste20
and Ste7. In the second case, we activated the pathway through
expression of STE12 under the control of the inducible GAL1
promoter. STE12 overexpression leads to transcriptional in-
duction in the absence of any upstream components or added
pheromone (47).
As shown in Fig. 4, Prr1 and Prr2 are both potent inhibitors
of transcriptional induction, in response to either STE11-4 (top
panel) or STE12 overexpression (bottom panel). In agreement
with previous reports, our positive control Fus3 is also a potent
inhibitor of transcriptional induction (48–50). When overex-
pressed, a portion of Fus3 is presumably in the unphosphoryl-
ated and catalytically inactive state. This pool may interfere
with the ability of any activate Fus3 to transmit a signal to
Ste12 (48). These data show that Prr1 and Prr2 (like Fus3)
regulate signaling downstream of Ste11, most likely at the
level of Ste12.
To determine whether signal inhibition requires the GST
FIG. 1. Overexpression of kinase-
GST fusions leads to diminished
pheromone-dependent growth arrest
response. Cells were transformed with
FUS3, PRR1, PRR2, YNR047w, KIN82,
or PTK2, all in the vector pYEX-4T-2,
plated, and exposed to sterile filter discs
spotted with a-factor (clockwise from bot-
tom: 0, 15, 25, 50, 60, and 75 mg) for 48 h
and then photographed. Depicted are the
four unknown protein kinases recovered
in the screen, Prr1, Prr2, Ynr047w, and
Kin82. Fus3 is the positive control. Ptk2
is the negative control. Rare colonies
within the zone of growth inhibition are
spontaneous sterile mutants.
FIG. 2. Overexpression of PRR1-GST or PRR2-GST leads to
diminished pheromone-dependent transcriptional induction.
Cells were cotransformed with a plasmid containing the pheromone-
responsive FUS1 promoter-lacZ reporter and a plasmid containing
FUS3-GST, PRR1-GST, PRR2-GST, or no insert (Vector; pYEX 4T-2).
Cells were treated with the indicated concentrations of a-factor, and
b-galactosidase activity was determined as detailed under “Experimen-
tal Procedures.” Data shown are typical of three independent experi-
ments performed in triplicate. Error bars, 6 S.E.
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moiety, each open reading frame was polymerase chain reac-
tion-amplified and cloned into another vector lacking any fu-
sion protein. As shown in Fig. 5, overexpression of Prr2 or Fus3
reduced the maximum response at 30 mM a-factor by 3.1- and
29.7-fold, respectively, compared with the vector control. This
level of inhibition is comparable with that observed for the GST
fusions (Fig. 2). In contrast, overexpression of Prr1 provided
almost no reduction, considerably less than the 1.24-fold reduc-
tion observed with Prr1-GST (Fig. 5 versus Fig. 2). Because
inhibition by Prr1 is largely dependent on the presence of GST,
we cannot rule out the possibility that Prr1 is only active as a
GST fusion protein. In contrast, the inhibition by Prr2, like
that of Fus3, is independent of the GST moiety.
Overexpression of Prr1 or Prr2 could inhibit signaling by at
least two different mechanisms. First, overexpression could
lead to an enhanced (perhaps unregulated) phosphorylation
and inhibition of a pathway component. Second, overexpression
of the kinase could lead to reduced phosphorylation of a sub-
strate protein, through competitive binding and inhibition of a
needed regulatory subunit or of a substrate protein (see below).
To distinguish between these possibilities, we prepared a mu-
tant version of Prr1 and Prr2 that lacks a conserved Lys es-
sential for kinase activity. If the competitive inhibition mech-
anism applies, wild-type and kinase-dead versions should be
equally inhibitory. For example, a kinase-dead form of Fus3
(Fus3K42R) has been reported to inhibit signaling when overex-
pressed, evidently through its ability to bind and inhibit its
substrates in competition with wild-type Fus3 (48–50). Alter-
natively, if the enhanced phosphorylation mechanism applies,
the kinase-dead enzyme should fail to inhibit. As shown in Fig.
6, Fus3K42R inhibits in this assay. However, the kinase-dead
version is slightly less potent than the wild-type counterpart.
This outcome suggests that inhibition by Fus3 overexpression
involves both competitive and enhanced phosphorylation mech-
anisms. Likewise, the kinase-dead version of Prr2 is a less
potent inhibitor than its wild-type counterpart. This suggests
that Prr2, like Fus3, acts through competitive binding, as well
as enhanced phosphorylation. By contrast, inhibition by
Prr1K225R was equal to that of wild-type Prr1. This result
supports the view that Prr1 inhibits the pheromone response
primarily through a competitive binding mechanism.
The ability to suppress both STE11-4 and GAL1-STE12 in-
dicates that Prr2 operates at the level of the transcription
factor Ste12. Ste12 activity depends in part on Fus3 binding
and phosphorylation. We therefore examined whether Prr2
inhibits Ste12 indirectly, through inhibition of Fus3. It has
been shown previously that pheromone activation results in
feedback phosphorylation of Ste7. This reaction provides a
particularly convenient indicator of Fus3 activity in vivo, be-
cause the resulting hyperphosphorylated species of Ste7 exhib-
its a markedly reduced mobility (;10 kDa) on SDS-polyacryl-
amide gel electrophoresis (35). Thus we used the Ste7 mobility
shift assay to determine whether Prr2 or Prr2K390R can inhibit
Fus3 activity. As shown in Fig. 7, pheromone induction caused
a typical shift in Ste7 mobility (Fig. 7, lane 1 versus lane 6). As
FIG. 3. Disruption of PRR1 or PRR2 does not alter pheromone-
dependent transcriptional induction. Gene disruption mutants
lacking FUS3 (fus3D), PRR1 (prr1D), or PRR2 (prr2D) were trans-
formed with the FUS1-lacZ reporter plasmid. Cells were treated with
a-factor, and b-galactosidase activity was determined as described
above. Data shown are typical of three independent experiments per-
formed in triplicate. Error bars, 6 S.E.
FIG. 4. Overexpression of PRR1-GST or PRR2-GST leads to
diminished transcriptional induction through activation by
STE11–4 or STE12. Cells were transformed with a plasmid containing
the FUS1 promoter-lacZ reporter, a plasmid that overexpresses either
a constitutively active allele STE11-4 (top panel) or wild-type STE12
(bottom panel), and a plasmid containing FUS3-GST, PRR1-GST,
PRR2-GST, or no insert (Vector; pYEX 4T-2). Cells were treated with
the indicated concentrations of a-factor or water, and b-galactosidase
activity was determined as detailed under “Experimental Procedures.”
Data shown are typical of three independent experiments performed in
triplicate. Error bars, 6 S.E.
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expected, overexpression of either Fus3 or Fus3K42R completely
inhibited pheromone-induced Ste7 phosphorylation. In con-
trast, overexpression of Prr2 or the catalytically inactive deriv-
ative Prr2K390R had no effect on Ste7 phosphorylation (Fig. 7,
lanes 9 and 10). Overexpression of Prr1 or Prr1K225R similarly
had no effect on pheromone-induced feedback phosphorylation
of Ste7 (data not shown). These results confirm that inhibition
of the pheromone-response pathway by Prr2 (and Prr1) occurs
downstream of the MAPK.
DISCUSSION
In recent years a number of eukaryotic genomes have been
sequenced, including that of humans, Drosophila melano-
gaster, Caenorhabditis elegans, and the yeast S. cerevisiae. The
wealth of information provided by these efforts will require the
development of more systematic approaches to the analysis of
gene function. Here we have tested a subset of the Saccharo-
myces genome, specifically the genes encoding likely protein
kinases. Our immediate goal was to identify novel kinase reg-
ulators of the pheromone-response pathway. A broader goal
was to assess the feasibility of such a systematic screening
method for functional genomic analysis in yeast and eventually
in mammals.
By screening a protein kinase-GST overexpression library,
we identified 12 kinase regulators of the pheromone response.
Five of the genes represent previously known components and
a regulator of the signaling pathway (STE7, STE11, FUS3,
YCK1, and KSS1). The remaining seven have not been shown
previously to act in this manner. The two most active regula-
tors, designated PRR1 and PRR2, were characterized further.
Overexpression of either PRR1 or PRR2 is able to diminish
signaling, as assessed by two standard bioassays of pheromone
sensitivity (Figs. 1 and 2). Gene disruption mutants have no
effect on signaling (Fig. 3). Both kinases appear to act late in
the pathway, as demonstrated by their ability to diminish
signaling by activated forms of STE11 and STE12 (Fig. 4),
without affecting the activity of the MAPK (Fig. 7). Inhibition
of signaling by PRR1, but not PRR2, is largely dependent upon
GST fusion (Fig. 5). Inhibition by PRR2, but not PRR1, is
dependent upon its kinase catalytic activity (Fig. 6). Thus our
genetic analysis indicates that the pheromone-response regu-
lators identified here act downstream of the MAPK and most
likely in conjunction with a terminal-signaling component
Ste12.
Future experiments will be aimed at finding the target of the
most potent regulator Prr2. One obvious candidate substrate is
Ste12. Ste12 is known to be heavily phosphorylated through
the action of Fus3 and Kss1 and almost certainly by other
kinases (18, 22, 23). Demonstrating that Prr2 phosphorylates
Ste12 may be difficult, however. The presence of multiple in-
dependent phosphorylation sites has frustrated efforts in the
past to identify kinases in addition to the MAPKs that act on
Ste12 (23).
Other candidate substrates include a number of DNA-bind-
ing proteins that also interact with Ste12, including Mcm1,
Mata1, Tec1, Kar4, Dig1, Dig2, and Ste12 itself. Ste12 ho-
modimers are needed for the expression of pheromone-induc-
ible genes in both a- and a-haploid cell types (12). Ste12-Tec1
heterodimers are needed for expression at promoters contain-
FIG. 5. PRR1 but not PRR2 requires GST for inhibition of
pheromone-dependent transcriptional induction. Cells were co-
transformed with a plasmid containing the FUS1 promoter-lacZ re-
porter and a plasmid containing FUS3, PRR1, PRR2, or no insert
(Vector; pYES2.1 TOPO). Cells were treated with the indicated concen-
trations of a-factor, and b-galactosidase activity was determined as
described above. Data shown are typical of three independent experi-
ments performed in triplicate. Error bars, 6 S.E.
FIG. 6. PRR2 kinase activity is required for full inhibition of
pheromone-dependent transcriptional induction. Cells were co-
transformed with the FUS1 promoter-lacZ reporter and a plasmid
containing either wild-type or kinase-dead (KR) forms of FUS3, PRR1,
PRR2, or no insert (Vector; pYES2.1/V5). Cells were treated with a-fac-
tor, and b-galactosidase activity was determined as described above.
Data shown are typical of three independent experiments performed in
triplicate. Error bars, 6 S.E.
FIG. 7. PRR2 does not alter Fus3/Kss1 phosphorylation of Ste7.
Immunoblots comparing phosphorylated (P-Ste7; upper arrow) and
non-phosphorylated (lower arrow) forms of Ste7 are shown. Strain
C699–32 (bar1::HisG ste7::ADE2) expressing Myc-tagged Ste7 (Ste7M)
from the CYC1 promoter (pNC318) and one of the following from the
GAL1,10 promoter is shown: lane 1, empty vector (pYES2.1/V5); lane 2,
Fus3; lane 3, Fus3-KR; lane 4, Prr2; lane 5, Prr2-KR; lane 6, empty
vector (pYES2.1/V5); lane 7, FUS3; lane 8, FUS3-KR; lane 9, PRR2; lane
10, PRR2-KR. KR, kinase-dead. Extracts were prepared from each
culture either before (right) or after (left) pheromone induction (50 nM
a-factor; 90 min). 150 mg of each extract was fractionated by SDS-
polyacrylamide gel electrophoresis (10%) and transferred to nitrocellu-
lose filters for immune detection of Ste7M using anti-Myc monoclonal
antibody and anti-mouse IgG conjugated to alkaline phosphatase.
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ing a filamentous growth response element (13, 15, 51, 52).
Ste12-Mcm1 heterodimers are needed for expression of a-cell-
specific genes in response to pheromone (13, 14). A ternary
complex involving Ste12, Mcm1, and Mata1 is needed for ex-
pression of a-cell-specific genes in response to pheromone (e.g.
MFa2). Conversely, a ternary complex involving Ste12, Dig1, or
Dig2 and either Fus3 or Kss1 (24, 25) can inhibit transcription
at pheromone-response elements (48, 50) or filamentous
growth response elements (49, 53), respectively. In principle,
Prr1/Prr2 could modulate Ste12 activity directly or indirectly
through phosphorylation of a Ste12-binding protein.
Prr1, and to a certain extent Prr2, may regulate signaling
through a mechanism that does not require kinase activity. We
showed that wild-type and kinase-dead forms of Prr1 were
equally active in their ability to inhibit the pheromone re-
sponse. The kinase-dead form of Prr2 was less active than its
wild-type counterpart (Fig. 6). In this regard, Prr2 behaves
very much like Fus3; a kinase-dead form of Fus3 inhibits
pheromone signaling, though less potently than the wild-type
version (Fig. 6). Inhibition of signaling by catalytically inactive
Fus3 has been attributed, at least in part, to its direct binding
and inhibition of Ste12 (48–50). In the absence of a sustained
signal, a dephosphorylated form of Fus3 accumulates, blocks
Ste12-mediated gene transcription, and permits cell cycle pro-
gression. Under pheromone-inducing conditions Ste7 phospho-
rylates and activates Fus3, and this leads to both removal of
inhibition (through dissociation) and activation (through phos-
phorylation) of Ste12. Thus, Fus3 can act as both an inhibitor
and an activator of Ste12, depending on its state of phospho-
rylation. A similar phenomenon has also been observed for
Kss1 (49, 50, 54). Taken together, these results suggest that
Prr2 behaves similarly to Fus3, able to function as both an
inhibitor and activator of Ste12.
Once the target of Prr2 kinase activity is found, we will
attempt to identify upstream activators of Prr2. One likely
candidate is the MAPK Fus3. Although the most intensively
studied substrates of MAPKs are transcription factors (55),
some substrates are themselves protein kinases (16, 66). Al-
though some MAPK kinase substrates act upstream in the
same pathway (Ste7, Ste11), it is unlikely that Prr2 acts up-
stream of Fus3, because Fus3 activity is not altered by PRR2
overexpression (Fig. 7).
There are other reasons to believe that Prr2 acts within the
nucleus. We identified three NLS motifs within Prr2 (Fig. 8B).
NLS are utilized for the import of proteins into the nucleus
from the cytoplasm through the nuclear pore complex (56).
Translocation of Prr2 to the nucleus from the cytosol and/or
activation of Prr2 within the nucleus may be involved in me-
diating the inhibition of pheromone signaling. Exploring these
areas may lead to new insights into the molecular mechanism
of the regulation of nuclear signal transduction.
Another issue is whether Prr1 or Prr2 exists as a dimer,
either as a homodimer or as a heterodimer with another regu-
latory protein. We have shown that the pheromone-response
regulation by Prr1 requires the GST moiety. Because the GST
moiety exists as a dimer (57), GST could activate Prr1 by
imposing homodimerization. Alternatively, GST might steri-
cally exclude binding by another subunit or a regulatory pro-
tein. Given the position at which Prr1 and Prr2 act in the
pathway (downstream of the MAPK) it seems likely that these
proteins do form some sort of dimer. Many MAPK substrates
exist as dimers, most notably transcription factors (55). More-
over, many MAPKs appear to undergo dimerization upon acti-
vation, which likely facilitates the phosphorylation of dimeric
substrates (58). Finally, biochemical (9, 59) and genetic (11, 60)
methods indicate that the MAPK scaffold protein Ste5 also
self-associates and exists as an oligomer in cell extracts. Ste5
mutants that cannot oligomerize (11) are unable to transmit
the pheromone signal (9, 11).
It is not certain why the prr1D and prr2D mutants lack any
signaling phenotype. The absence of an observable phenotype
for the prr1D mutant might be expected, because only the GST
FIG. 8. Prr2 and its homologues in S. cerevisiae. A, Cladogram
depicting the Npr1/Hal5 family of protein kinases in S. cerevisiae. A
tree depicting the entire kinase family was described previously (65).
The closest Prr2 homologues are Npr1, YDL025c, and YOR267c. Ste20,
Snf1, and Chk1 are not members of the Npr1/Hal5 family but are
closely related. B, Prr2 protein sequence. Prr2 contains all three of the
classical nuclear localization signals (black highlight) found in animal
proteins, and they are as follows: a four-residue pattern within the
protein kinase domain (KKKR), a seven-residue pattern within the N
terminus (PKGRLRK), and a bipartite element also located within the
N terminus (RKHSYTTSLSSIKRLFK). Also indicated is the critical
lysine mutated to arginine (K390R) creating the dead kinase version of
Prr2 (clear box). The protein kinase domain is also indicated (gray
highlight).
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fusion protein inhibits the response. However, this explanation
does not apply to the prr2D mutant. One possibility to consider
in this case is that a closely related gene may compensate for
the loss of Prr2. For example, loss of STE20 is compensated in
part by the closely related gene, CLA4 (14, 61–63). In fact, at
least three other kinases appear closely related to PRR2, in-
cluding NPR1, YDL025c, and YOR267c (Fig. 8A). Analysis of
double, triple, and quadruple gene disruption mutants are in
progress and may reveal some defect in signaling (if indeed
these mutants are viable). Alternatively Prr2 activity might
regulate both positive and negative components of the path-
way. If this were the case, the deletion mutation could be
without a phenotype. For example, it has been established that
the MAPK Kss1 is a component of the pseudohyphal response
pathway, yet the kss1D deletion mutant has no phenotype,
because Kss1 has both positive and negative regulatory roles in
the pathway (49, 50).
In conclusion, Prr2 is one of a growing list of proteins that
modulate pheromone signaling and which act downstream of
the MAPK. Clearly, much remains to be learned about its
mechanism of action, where it is located, and how it is regu-
lated. The availability of the kinase-GST fusions will facilitate
the identification of proteins that regulate, or are regulated by,
this novel kinase. Recent advances in the use of mass spectrom-
etry for proteomics should make it feasible to perform a global
analysis on S. cerevisiae cells to determine all proteins that are
phosphorylated in a Prr2- or Prr1-specific manner (64). More
generally speaking, the approach used here serves as a model
for identification and characterization of unknown gene prod-
ucts, as they are identified through genome sequencing
programs.
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